CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

Cancer Treatment in Mexico: CureMatch Extends Precision Medicine Technology

Cancer Treatment in Mexico: CureMatch Extends Precision Medicine Technology
PartnersPress

When it comes to cancer treatment in Mexico, just like in the United States, many cancer patients and their doctors still rely on traditional “one-size-fits-all” methods of care. CureMatch is looking to extend Precision Medicine technology to doctors and facilities responsible for any cancer treatment in Mexico.

SAN DIEGO, CA – June 5, 2018: CureMatch, Inc. is now offering Personalized Combination Therapy® options to cancer care hospitals and oncologists in Mexico. By implementing collaborative, culturally sensitive initiatives, CureMatch will support long-term partnerships throughout Mexico to improve cancer treatment outcomes.

CureMatch is a recognized U.S. knowledge leader invited to participate in “Consuls of Mexico & U.S. Leaders visit to Baja California – CLinBC 2018” and share biotech advancements in oncology with municipal, state and federal governments.

Image result for Marcela Celorio, Consul General of Mexico clinbc

Ambassador Marcela Celorio, Consul General of Mexico in San Diego, stated, “The strength of the Cali-Baja mega region, with a combined population of 6.5 million and an economy of $230B (USD), depends on commitment to binational collaboration. Precision medicine technology paves the way for better cancer care for patients on both sides of the border.”

In Mexico, as well as the United States, most cancer patients and their doctors continue to rely on traditional “one-size-fits-all” methods of care. Typical treatments and procedures address a particular type or origin of tumor rather than the unique nature of each individual patient’s cellular mutations. The solution lies in matching drug treatments to genomic sequencing data. Today, precision medicine is viewed by both developed and developing countries as the future of oncology. Through this emerging approach, CureMatch ranks the top mono-therapies, two-drug combinations, and three-drug combinations (sorting over 4.5M possibilities) to assist doctors’ prescriptions.

Cancer Statistics in Mexico

Cancer is responsible for approximately 13% of the total deaths in Mexico annually. By 2020, over 216,000 new cases of cancer and 23,000 deaths are expected given current trends. These incidence estimates are associated with a total indirect cost of $1.01B (Salud Publica Mex). Current efforts to combat cancer have resulted in positive outcomes, yet despite the progress, Mexico still faces challenges in the areas of infrastructure, accessibility, and innovation.

CureMatch has been working with government officials and hospitals in Mexico to create successful and sustainable precision oncology programs. Personalized Combination Therapy® based on next-generation genetic testing enables oncologists to make effective treatment decisions at a faster pace. Elevating the standard of cancer care to improve survival and clinical outcomes for many cancer patients seeking treatment in Mexico is the goal.

Mayor of Tijuana with Ambassador Carlos Manuel Sada Solana

(l-r) Pictured: Ambassador Carlos M. Sada (Undersecretary for North America), Juan Manuel Gastélum, (Mayor of Tijuana), Eduardo Bernal (Consul of Mexico in Texas), Susan Leonard (CureMatch PR), Stephane Richard (CureMatch CEO).

Juan Manuel Gastélum Buenrostro, Municipal President of Tijuana welcomed CureMatch to Mexico, stating, “We appreciate the interest and support demonstrated towards the hospitals and doctors working in the treatment of cancer in our region. The Mayor’s Office is committed to promoting the development of companies like CureMatch, who work for the welfare of the people of Tijuana, and especially in this case, with a mission as important as making precision medicine available to all.”

 

“CureMatch is in an advantageous position, both geographically and technologically, to create a paradigm shift for cancer treatment on both sides of the U.S. – Mexico border,” stated Stephane Richard, Ph.D, President and Chief Executive Officer of CureMatch.

###

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com

CureMatch Media Contact:
Name: Larissa Anderson
Company: CureMatch
Phone: (858) 859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data